{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"}],"units":"Participants"}],"description":"Participants with treatment-induced and treatment-enhanced anti-drug antibodies. The clinical relevance of anti-rituximab antibody formation in RITUXAN treated pemphigus vulgaris (PV) participants is unclear.","groups":[{"description":"Participants received rituximab by IV infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria had been met. Participants also received MMF matching placebo orally twice daily (every 12 hours, Q12H) from Day 1 to Week 52.","id":"OG000","title":"Rituximab (RTX)"}],"paramType":"NUMBER","populationDescription":"The safety population (all participants who were randomized and received any part of an infusion of study drug), only participants for whom data were collected are included in the analysis.","reportingStatus":"POSTED","timeFrame":"Baseline up to 52 Weeks (up to CCOD of 28 November 2018)","title":"Percentage of Participants With Anti-Drug Antibodies (ADA)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}